Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774790 | 0.88 | MAPT (0.64) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL5773983 | 0.74 | GLA (0.53) | MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL5777386 | 0.74 | LMNA (0.47) | MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL22500317 | 0.74 | SHMT2 (0.61) | DGAT1RAB9ACYP1A2MAPTNPC1 | |
| SCHEMBL17683481 | 0.74 | NPC1 (0.50) | RAB9ACYP1A2MAPTNPC1SMN1; SMN2 | |
| SCHEMBL5773818 | 0.74 | PORCN (0.57) | RAB9AMAPTSMN1; SMN2LMNAWNT3A | |
| SCHEMBL22500647 | 0.73 | MAPT (0.65) | DGAT1RAB9ACYP1A2MAPTNPC1 | |
| SCHEMBL21379546 | 0.73 | MAPT (0.70) | DGAT1RAB9ACYP1A2MAPTNPC1 | |
| SCHEMBL5773299 | 0.73 | MAPT (0.54) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL2169030 | 0.73 | MAPT (0.78) | DGAT1RAB9ACYP1A2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | DGAT1 560/4885RAB9A 3076/4885CYP1A2 68/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | DGAT1 371/4885RAB9A 3507/4885CYP1A2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.